trending Market Intelligence /marketintelligence/en/news-insights/trending/DEoyvu6pFACKhSQXshYDcg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sigma Healthcare rejects Australian Pharmaceuticals' takeover offer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sigma Healthcare rejects Australian Pharmaceuticals' takeover offer

Sigma Healthcare Ltd. said its board rejected Australian Pharmaceutical Industries Ltd.'s takeover offer, noting the transaction is not in the best interests of its shareholders.

Australian Pharmaceutical Industries, or API, offered to acquire all the shares in Sigma for 0.31 of an API share and 23 Australian cents in cash per Sigma share. API already owns 12.95% of Sigma Healthcare.

Sigma's board said significant shareholder value could be realized if it continues as a stand-alone company when it implements cost cutting initiatives. These measures could result to more than A$100 million of cost savings in the next two years, the company added. Meanwhile, a merger with API will generate A$60 million of synergies.

API is reviewing its shareholding in Sigma, the company said in a March 13 news release.

Rowville, Australia-based Sigma Healthcare is also focused on wholesale and distribution of pharmaceutical products.